- Home
- HSCS vs APM Comparison
HSCS vs APM Comparison
Compare HSCS & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSCS | APM |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United Kingdom |
| Employees | 12 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 7.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HSCS | APM |
|---|---|---|
| Price | $2.01 | $0.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 13.2K | ★ 66.1K |
| Earning Date | 03-16-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.89 | $0.65 |
| 52 Week High | $6.47 | $4.47 |
Technical Indicators
Market Signals| Indicator | HSCS | APM |
|---|---|---|
| Relative Strength Index (RSI) | 36.18 | 50.57 |
| Support Level | $1.95 | $0.77 |
| Resistance Level | $2.60 | $1.11 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 20.42 | 42.53 |
Price Performance
Historical ComparisonAbout HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.